Trade Mark Journal No.2026/029 17 July 2026
WO0000001925748 (5,44)
Office of origin: United States of America
Date of International Registration:29 April 2026
Date of designation in the UK:
29 April 2026
The mark consists of two overlapping hexagon shapes formed by a series of irregular polygons with curved corners.
International priority date claimed: 18 November 2025
(United States of America)
(99503009)
- Class 5
- Pharmaceutical preparations and substances for the treatment of neurodevelopmental and neurodegenerative diseases and disorders, leukodystrophy, demyelinating diseases and disorders, and hypomyelinating diseases and disorders; pharmaceutical preparations and substances for the treatment of glial fibrillary acidic protein-associated diseases and disorders, alexander disease, seizures, ataxia, motor function disorders, cognitive function disorders, dysphagia, and swallowing disorders; pharmaceutical preparations and substances for the treatment of autosomal dominant, autosomal recessive, genetic, neurologic, parasympathetic system, neuromuscular system, skeletomuscular system, central nervous system, epileptic, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, metabolic, autoimmune and lymphoproliferative diseases and disorders; pharmaceutical preparations containing zilganersen.
- Class 44
- Providing health information; providing healthcare information; medical information services provided via the Internet.
Ionis Pharmaceuticals, Inc.
Representative: Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP, 601 Massachusetts Ave., NW, IP DOCKETING, Washington DC 20001, UNITED STATES OF AMERICA